1 to 9 of 13 results

Briefs: Depomed drops Sefelsa after CRL: Sun Pharma stalking Meda?


US specialty drugmaker Depomed (Nasdaq: DEPO) says that Food and Drug Administration issued a complete…

DepomedMedaMergers & AcquisitionsMetabolicsNorth AmericaPharmaceuticalRegulationResearchSefelsaSun Pharmaceutical Industries

OPKO Health to acquire PROLOR Biotech in $480 million stock deal


Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X


In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

Takeda acquires vaccine maker LigoCyte; signs multi-drug discovery deal with Advinus


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it is to acquire privately-held US vaccine…

Advinus TherapeuticsInflammatory diseasesLicensingLigoCyteMergers & AcquisitionsMetabolicsNeurologicalPharmaceuticalTakeda PharmaceuticalsVaccines

Cornerstone acquires Cardiokine


US specialty drugmaker Cornerstone Therapeutics (Nasdaq: CRTX) said yesterday that it has acquired Cardiokine,…

Cardio-vascularCardiokineCornerstone TherapeuticslixivaptanMergers & AcquisitionsMetabolicsPharmaceutical

Astellas views options for Prosidion subsidiary, including its sale


Japanese drug major Astellas Pharma (TSE: 4503) says that it has engaged Citigroup Global Markets to…

Astellas PharmaDiabetesMergers & AcquisitionsMetabolicsOSI PharmaceuticalsPharmaceuticalProsidion

Positive Ph II five-year results with Genzyme’s alemtuzumab in MS patients could prompt higher bid from Sanofi, observers suggest


US biotech major Genzyme Nasdaq: GEN), which is fending off an unsolicited takeover bid from France’s…

AlemtuzumabBayerBiotechnologyCampathGenzymeMergers & AcquisitionsMetabolicsNeurologicalPharmaceuticalResearchSanofi-Aventis

Abbott Labs gives up on vaccines unit sale, as no adequate bidders in sight; heart risks reported with obesity drug Meridia


US health care major Abbott Laboratories (NYSE: ABT) has apparently given up its attempt to divest the…

Abbott LaboratoriesMergers & AcquisitionsMeridiaMetabolicsPharmaceuticalRegulationResearchSolvayVaccines

1 to 9 of 13 results



Back to top